Logo

ASPCR

A SPAC III Acquisition Corp.

ASPCR

A SPAC III Acquisition Corp. • NASDAQ
$0.16 ▲ 0.00% (+0.00)
Market Cap $1.08 M
52w High $0.18
52w Low $0.16
Dividend Yield 0%
P/E 0
Volume 159
Outstanding Shares 6.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $173.955K ▼ $480.352K ▲ 0% $-0.11 ▼ $0 ▲
Q2-2025 $0 $267.036K ▲ $379.939K ▼ 0% $0.047 ▼ $-267.036K ▼
Q1-2025 $0 $233.878K ▼ $413.202K ▲ 0% $0.051 ▲ $-234K ▲
Q4-2024 $0 $540.328K ▲ $-180K ▼ 0% $0 ▲ $-540K ▼
Q3-2024 $0 $38.778K $-38.778K 0% $-0.03 $-38.778K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.063M ▼ $63.361M ▲ $529.565K ▲ $975.004K ▼
Q2-2025 $1.069M ▼ $62.776M ▲ $425.036K ▲ $1.898M ▼
Q1-2025 $1.12M ▼ $62.25M ▲ $278.705K ▼ $61.971M ▲
Q4-2024 $1.599M ▲ $62.075M ▲ $517.334K ▲ $61.558M ▲
Q3-2024 $0 $82.25K $269.604K $-187.354K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $480.352K ▲ $-5.877K ▲ $0 $0 $-5.877K ▲ $-5.877K ▲
Q2-2025 $379.939K ▼ $-51.101K ▲ $0 $0 ▲ $-51.101K ▲ $-51.101K ▲
Q1-2025 $413.202K ▲ $-203.059K ▲ $0 $-276.221K ▼ $-479.28K ▼ $-203.059K ▲
Q4-2024 $-179.605K ▼ $-354.934K ▼ $0 $61.954M ▲ $1.599M ▲ $-354.934K ▼
Q3-2024 $-38.778K $-118.953K $0 $0 $0 $-118.953K

Five-Year Company Overview

Income Statement

Income Statement ASPCR is a SPAC, so it has no real operating business and, based on the data shown, essentially no revenue or profit history of its own. The income statement is mostly a placeholder until the merger closes. The real economic story belongs to Bioserica, which will become the operating company after the transaction. For now, past earnings figures for ASPCR provide very little insight into the future combined business, and investors need to treat current financials as largely non‑indicative of the go‑forward picture.

Balance Sheet

Balance Sheet The balance sheet shown for ASPCR is effectively empty, which is typical for a blank‑check company that mainly holds cash in a trust account and has minimal operating assets or liabilities. The real balance sheet strength or weakness will depend on how much cash is actually delivered at closing, how much is used to fund growth and pay costs, and what Bioserica’s own asset and debt profile looks like once combined. Until those details are clear, the reported balance sheet for ASPCR on its own does not reflect the true future financial position.

Cash Flow

Cash Flow Reported cash flow data is also essentially flat, again reflecting that ASPCR is not running a normal operating business. In practice, SPAC cash flows are dominated by fundraising proceeds, interest on trust cash, and deal‑related expenses, none of which show the earning power of the future operating company. The key cash‑flow question is whether the merger will leave Bioserica with enough net cash after redemptions, fees, and integration costs to fund its expansion plans comfortably.

Competitive Edge

Competitive Edge As a SPAC, ASPCR has no products, customers, or market share. The competitive angle really sits with Bioserica, the merger target. Bioserica appears to have a differentiated position in bio‑based, biodegradable antimicrobial textiles, backed by proprietary materials, a specialized manufacturing process, and a sizable portfolio of patents and trademarks. Its focus on sustainable, skin‑friendly antimicrobial fabrics fits well with trends in health, hygiene, and environmental regulation. That said, it competes in a global textile space that is crowded and price‑sensitive, so winning large brand and retailer partnerships and scaling production efficiently will be critical tests of its competitive strength.

Innovation and R&D

Innovation and R&D Innovation is a clear focal point for Bioserica. The company has developed a proprietary bio‑based antimicrobial fiber, using renewable polymers and an in‑house antimicrobial agent, and it has embedded this into both intermediate materials (fibers) and finished goods (such as socks and masks). Its patent and trademark filings, plus claims of unique know‑how in producing certain components, suggest a meaningful technology moat. Future value will depend on how well Bioserica can keep improving performance, reducing production costs, broadening applications (for example into medical and institutional textiles), and translating lab advantages into consistent, large‑scale manufacturing and branded products.

Summary

ASPCR today is primarily a financial shell with minimal historical operating data, so traditional financial analysis of its past results offers little guidance. The real story is the proposed merger with Bioserica, a specialist in sustainable antimicrobial textiles. On the positive side, Bioserica appears to bring proprietary technology, strong intellectual property, and good alignment with long‑term trends in sustainability and hygiene. On the risk side, there is execution uncertainty around closing the deal, the level of cash that will actually be available post‑merger, the challenge of scaling manufacturing and sales, and the need to prove broad market adoption in a highly competitive, cost‑driven industry. Overall, any assessment of ASPCR has to be framed as an evaluation of the future Bioserica business and its ability to turn its technical edge into durable, profitable growth.